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Due to their natural origin, apparent low oral toxicity, eﬀectiveness, and accessibility without a medical prescription, the
anthranoid laxatives are a popular remedy for constipation and are frequently used abusively. Therefore, it is important to
characterize its harmful and/or toxic eﬀects. The sennosides, main active metabolites of senna, exhibit a very low toxicity in rats,
and its genotoxic activity in bacterial strains as well as mammal cells was classiﬁed as weak in those cases where it was shown to
be signiﬁcant. The toxicological and mutagenic status of the crude extract of senna, however, is not as well characterized, and it
is necessary to do so since it is frequently, and at the same time incorrectly, believed that the chronic use of anthranoid laxatives
is a risk factor for the development of colorectal cancer. The objective of this article was to review the information that arises in
various scientiﬁc medical databases using key words such as senna, sen, Senna alexandrina, Cassia angustifolia, sennosides, laxative
toxicity,mainlyISIandnon-ISIarticlesofjournalswithaneditorialcommittee.Webpagesofproductsorcompaniesthatpublicize
or commercialize this type of laxative were not included. This analysis establishes that (1) there is no convincing evidence that the
chronic use of senna has, as a consequence, a structural and/or functional alteration of the enteric nerves or the smooth intestinal
muscle, (2) there is no relation between long-term administration of a senna extract and the appearance of gastrointestinal tumors
or any other type in rats, (3) senna is not carcinogenic in rats even after a two-year daily dose of up to 300mg/kg/day, and (4)
the current evidence does not show that there is a genotoxic risk for patients who take laxatives containing senna extracts or
sennosides.
Copyright © 2009 M. A. Morales et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Our current lifestyle has led to an important increase in
the demand for laxatives, medicinal products that induce
or contribute to defecation. Their high demand is clearly
established:in1995,itwasestimatedthat25%ofwomenand
10% of men in Germany considered they had diﬃculty to
defecate and suﬀered constipation [1].
Along with analgesics, laxatives are the most commonly
obtained medicines by patients without consulting a doctor.
Therefore, they could be easily used inadequately and
abusively. In Germany sales ﬁgures of around 39 million
units per year, with a value of DM 400 million [1], and in
the United States around USD 600 million of laxatives are
sold every year [2, 3].
The commercialization of laxatives is greater every year
and covers broad sectors of modern society, where its use
is observed in diﬀerent economic strata and diﬀerent age
groups. This is a cause for concern and leads to a permanent
analysis of risks which could be associated to the massive use
of these types of medicines.
Among the most used laxatives being self-administed
or prescribed by a physician, we ﬁnd that senna infusions,
bisacodyl, sodium picosulphate, sodium docusate, stimu-
lating laxatives, and lactulose are considered osmotic-type
laxatives.2 Journal of Toxicology
From its introduction by the Arabs in the XIX century,
the anthranoid laxatives have been widely used around the
world. Among the plants that contain anthranoid laxatives,
Senna (Senna alexandrina or Cassia angustifolia) is the most
used. Due to their natural origin, apparent low oral toxicity,
eﬀectiveness, and accessibility without a medical prescrip-
tion, the anthranoid laxatives are a popular medicament for
constipation, frequently used abusively.
There is an important need, therefore, to characterize
the potential harmful and/or toxic eﬀects of the anthranoid
laxatives. The derivatives are obtained from leaves and/or
dried pods of Senna alexandrina, or from the direct use of
the plant parts, separately or mixed.
The anthranoid compounds are classiﬁed in anthrones
(rhein anthrone), anthraquinones (aloe-emodin, chryso-
phanol rhein) and dianthrones (sennosides), and are present
in plants mainly as sugar derivatives. Since the β-glycosidic
bond is resistant to acid digestion and to α-glycosidase
activity in the small intestine, the anthranoid glycosides
are not absorbed in the small intestine. Instead, they are
maintained as prodrugs until they reach the large intestine
where they are metabolized to the active drug, the aglicone
rhein anthrone for the β-glycosidase and reductase activity
of the intestinal ﬂora [4, 5].
Senna contains various anthranoids, where the most
important are sennosides A and B; followed by aloe-emodin,
emodin, and chrysophanol [6]. The sennosides, main active
metabolite of senna, show a very low toxicity in rats [7]a n d
theirgenotoxicactivityinbacterialstrainsaswellasmammal
cells, in the cases where it was signiﬁcant, was classiﬁed as
weak [8–11].
The toxicological and mutagenic status of the senna
crude extract, however, is less characterized. In a study by
Hietala et al. [7], the laxative eﬀect and the acute toxicity
of certain fractions of senna extracts in rats were investi-
gated. The same tests were carried out with various pure
anthraquinone derivatives in senna pods. Results showed
that the laxative and toxic components could be separated
from pods and senna extracts. The most powerful laxative
components, sennosides A + B and the V fraction (with
relative potentials of 1 and 0.9, resp.) have the lowest toxicity
(intravenous toxicity relative to 1 and less than 1) while the
fractions with very low laxative activity (rhein-8-glucoside
and fraction IV with relative potentials of 0.56 and 0.05)
have the highest acute toxicity (relative toxicities of 10 and
32, resp.). This suggests that there are other active molecules
in the senna extract that could be responsible for its toxicity.
Anthranoids such as chrysantine, hidroxyanthraquinones,
presenting in trace concentrations in the extract, show a
diﬀerent and highly controversial toxicological status to the
sennosides. The hydroxyanthraquinones emodin and aloe-
emodingavepositiveresultsingenotoxicassaysinSalmonella
typhimurium, V79-HGPRT, rat hepatocytes, and mouse
ﬁbroblasts [12], however, in another study, such genotoxicity
was not observed [10]. In a study by Mori, the induction
of neoplasms in the intestine, stomach, and rat liver,
subjected to a diet containing 1% hidroxyanthraquinones
for 480 days, was induced [13]. It is worth mentioning
that these eﬀects were only observed at extremely high
doses and prolonged treatments. Other studies have not
found mutagenic eﬀects for these compounds. However, it
is necessary to precisely pinpoint the possible harmful eﬀects
oftheanthranoidlaxatives,sincerecentlyandfromresultsby
Siegers, it has been suggested that the chronic use of laxatives
such as aloe (Aloe spp.), frangula (Rhamnus frangula), and
cascara sagrada (Rhamnus purshiana DC) could constitute
a risk factor for the development of colorectal cancer
[14].
The objective of this article was to review scientiﬁc-
medical publications found in diﬀerent databases (Toxnet,
Ovid, IBIDS, ScienceDirect, Scirus, PubMed) with keywords
such as senna, sen, Senna alexandrina, Cassia angustifolia,
sennosides, and laxative toxicity. Web pages of products and
companies that publicize or commercialize these types of
laxatives were not included.
2. InhibitoryEffects of the Motilityand
Secretions of the Colon
The oral administration of sennosides (20–30mg/kg) to
fasting dogs induces a strong and prolonged inhibition of
the myoelectric activity of the colon that is evident after a
delay of 6–10 hours that corresponds to the orocecal transit
and to the metabolism in the colon accompanied by an
abundant diarrhea. When the sennosides are administered
1 hour prior to feeding, the habitual postprandial increase
of colon motility does not appear. The modulation of colon
motility by the sennosides has been broadly documented
and the appearance of 3 to 10 giant contractions of high
amplitude has been conﬁrmed under its eﬀect. These single
contractions propagate in the second portion of the colon
at a velocity of 0, 5–2cm/min. The elimination of liquid
faecal matter has been associated to these contractions. It
has also been conﬁrmed that these contractions are not only
produced by sennosides but also by other compounds such
as guanethidine, neostigmine, castor oil, and intraluminal
hypertonic glucose [15].
There is a direct inﬂuence on intestinal epithelial cells
after the administration of the sennoside metabolite rhein-
anthrone. At low doses, there is a change in cellular form and
of the organelles clearly related to an increase in metabolism.
High doses of rhein-anthrone induce apoptotic changes.
It seems that the interaction between epithelial cells and
the monocyte-type cells also induces the release of type E
prostaglandins. When rhein-anthrone is added to a group
of epithelial cells and mononuclear peripheral blood cells,
there is a 140% increase of the control value of PGE2. This
ﬁnding indicates that rhein-anthrone is activating intestinal
immune system components and may induce the secretion
and motility [16].
The oral administration of 50mg/kg of sennosides
modiﬁes the net secretion of water, Na+ and Cl− after 6
hours, a return to normal values occurs during the next 18
hours. After 24 hours, a signiﬁcant increase in the secretion
of K+ and Ca++ is also observed. The sennosides do not
modify the activity of the Na+− K+ pump of the mucosa
nor of the phophodiesterase enzyme; the levels of cAMP do
not vary either [17].Journal of Toxicology 3
3.ToxicityBackground
At a reproductive toxicity level, by 1986, U. Mengs had estab-
lished that the intragastric administration of sennosides did
not induce embryolethal, theratogenic, or fetotoxic eﬀects.
In his assays, using rats and rabbits, he also determined
that the sennosides did not have an eﬀect on the postnatal
development of young animals, on their mother’s behavior,
nor on the masculine or feminine fertility [18].
In 1987, Hietala et al. [7] investigated the laxative and
toxic activity using diﬀerent fractions of senna on mice.
Their results showed that it was possible to identify the
laxative components of those components that showed an
acute toxic activity. These studies, however, only considered
acutetoxicity(24hours)andwerecarriedoutusingveryhigh
doses [19]. The sennosides were classiﬁed as not very toxic in
rats and mice after administrating an oral dose. The LD50
values were 5000mg/kg in both species. Whatever the case,
the cause of death was probably due to an intense water and
electrolyte loss following an intense diarrhea.
In subacute studies with rats and dogs to which a
maximum dose of 20mg/kg and 500mg/kg was adminis-
tered, respectively, the sennosides did not cause local nor
systemic toxicity. A low weight increase was observed in
the rat kidneys which was irrelevant. In a more prolonged
study in rats to which a dose of up to 100mg/kg was
administered, no toxic eﬀects were observed after 6 months
[20]. The eﬀects on food consumption, weight gain, and
some biochemical parameters, in addition to slight renal
lesions, were interpreted as secondary eﬀects that arise as a
consequence of a chronic diarrhea. In the same study, no
abnormal results were observed in neither mutagenic nor
reproductive tests.
Another toxicity study designed a treatment of rats with
senna fruit extracts 1, 25, 100, and 300mg/kg/day for 104
weeks. Based on clinical signs related to the laxative eﬀect,
such as the mucosity of the faeces, the 300mg/kg/day dose
was considered to be the maximum tolerated dose [21]. At
this dose, the animals reduced their body weight, increased
their water consumption, and experienced notable changes
ofelectrolyteswithincreasesinK+ andCl− intheplasmaand
decreases in Cl−,N a +,a n dK + in the urine. The variations
in electrolytes are adaptative changes to the laxative eﬀect of
senna.
4. Morphological Changes
After a gastric administration of 100mg of sennosides/kg
body weight, morphological changes are not observed in the
rat colon. In the electronic microscopy examen, no damage
in the intramural nervous tissue appeared [22].
According to Dufour and Gendre, in 1988, some animal
and human studies revealed damages in the myenteric plexus
and the colon epithelium, but they recognized that other
studies had revealed the inexistence of such changes under
similar treatments [23]. These same authors carried out a
histological and ultrastructural study to try and evidence the
toxicity of sennosides in rats, acknowledging that they were
unable to ﬁnd intestinal mucosal damage after a long-term
treatment. The comparison of the eﬀect of the sennosides
and an anthracenic derivative 1,8-dihidroxyanthraquinone
on the jejunum and colon of rats showed that only the
synthetic compound caused anomalies in the myenteric





for 4-5 months with sennosides administered in drinking
water. A decrease in the body weight was observed while
the colon weight increased in relation to the body weight
of the animals tested. The determination of the number of
neurons in the rat colon was not aﬀected but an increase in
relation to the controls was observed in mice. No evidence
was obtained of destruction by toxicity or variation in the
neuron population; the appearance of isolated somas or
axons was not observed by antibody staining, which would
have detached from the myenteric plexus. It was concluded
that senna did not destroy the myenteric neurons from the
rat or mouse colon [24].
It has been shown that the sennosides induce cytochem-
ical changes in epithelium cells of the cecum, rectum, and
colon of rats. After 12 weeks of treatment, an increase in the
total acidic content of mucine with a decrease of sulfomucin
and increase of sialomucin was observed. An increase in
the expression of cytokeratin AE1 was also exhibited. The
results were interpreted as being of functional origin, and
the association to early precancerous lesions was discarded
[25].
A light and electronic microscope study in intestine of
Guinea pigs treated for 14 consecutive days with senna,
sennosides, danthron, and bisacodyl by gastric intubations
showed a darkening of the mucous del cecum and the
ascending colon except the group treated with bisacodyl.
A degeneration of the cytoplasm and an increase of the
apoptosisontheepithelialsurfaceofthecolonwereobserved
with all the laxatives. The intestinal changes were more
accentuated in the cecum and decreased toward the distal
region of the colon. It was concluded that the morphological
changes in the large intestine were similar in the treatments
with anthranoid and nonanthranoid laxatives, however, the
pigmentsfoundinthemacrophagediﬀeredincolorandwere
not always detected macroscopically [26].
In 1968 and 1972 preliminary evidences appeared that
led to a certain unease of the potential damaging eﬀect of
the stimulating laxatives [27, 28]. These initial investiga-
tions proposed that the laxatives containing anthraquinones
induced degenerative changes in the nervous tissue of the
colon; however, when analyzed by various authors [29–
31], these evidences received wide criticism due to the
methodology used.
Recent results have undermined the importance of
preliminary observations. In rats that were subjected during
two years to a treatment with puriﬁed senna extract in daily
doses of 0, 5, 15, and 25mg/kg, administered with drinking
water, it was discovered that no ultrastructural changes were
produced in the myenteric plexus of the colon and jejunum
[32].4 Journal of Toxicology
Although the stimulating laxatives can cause structural
damage to the surface of the intestinal epithelial cells, the
damage results from an uncertain functional signiﬁcance;
there is no convincing evidence that its chronic use brings
as a consequence a structural and/or functional alteration of
the enteric nerves or the smooth intestinal muscle [33].
A clinical study was designed to determine the eﬀects
of sennosides on the histology of the colon mucosa and
in the intestinal preparation for the diagnostic exam [34].
A number of 84 patients received a maximum of 150mg
sennosides A and B, and an intestinal wash was carried
out with 3–5L; the controls only received the intestinal
wash solution. The samples from the patients treated with
sennosides showed a marked increase in the inﬁltration of
the lamina propria by mononuclear cells. With respect to
the tolerance or quality of the intestinal preparation, there
were no signiﬁcant diﬀerences. However, because of the
microscopic variations that appeared, the use of laxatives
containing sennosides was not recommended in patients
who were preparing for colonic biopsies [34].
On the other hand, a recent study has concluded that
an elevated dose of oral senna is a valid alternative to
the conventional use of an intestinal wash solution with
polyethylene glycol and electrolytes in the preparation of
patients for a colonoscopy. The incidence of adverse eﬀects
was similar in both alternatives and patients who used senna
commented on less nauseas and vomiting though more
abdominal pain [35].
In the necropsy of rats treated for 13 consecutive weeks
with a senna preparation, the highest dose of which was
1500mg/kg/day, a discoloration of the kidneys was observed
together with histopathological changes. The latter was
observed starting fromthe 300mg/kg dose and consisted of a
slight-to-moderate tubular basophilia and pigment deposit.
This, however, did not correlate to functional changes in
the kidney using the determination of set parameters in the
laboratory.Likewise,aslighthyperplasiainthelargeintestine
was observed. After an eight-week suspension of the use
of the laxative, no histopathological anomalies were found,
with the exception of the brown pigmentation of the kidneys
[6].
Another toxicity study designed a rat treatment with
senna fruit extracts 0, 25, 100, and 300mg/kg/day for 104
weeks. In the necropsy, a dark discoloration was observed
on the kidneys of all the groups treated. In the histology,
changesinthekidneysofalltheanimalsofthegroupstreated
were observed that included a slight-to-moderate tubular
basophilia and pigment deposits. Furthermore, slight-to-
moderate hyperplasia was conﬁrmed in the colon and the
cecum [21]. These histological changes were reverted once
the treatment was suspended [6].
5.MelanosisColi andApoptosis
A similar condition to the human melanosis coli has been
observed in the large intestine of the guinea pig after a daily
administration of the anthraquinone danthron. Each treat-
ment provokes a transitory and dose-related wave of apop-
tosis on the surface of colon epithelial cells. The majority
of the apoptotic bodies are phagocytosed by intraepithelial
macrophages and transported through the fenestra of the
basal epithelial membrane to the lamina propria. Here, the
apoptotic bodies transform into typical lipofucsin pigments
in the lysosomes of the macrophages. The continuous
administration of danthron provokes a progressive accu-
mulation of pigmented macrophages on the intestinal wall
while the migration of pigmented macrophages toward the
lymphatic nodes region provokes, the sequential loss of the
pigmented cells from the superﬁcial and deep lamina pro-
pria,oncetheadministrationofdanthronaceases,suggesting
a similar process in the formation of pigment in man [36].
Melanosis coli is experimentally induced using anthra-
noid laxatives [37] and has been considered for a long time
as a pigmentation that does not provoke damage in the colon
and rectum and which is associated with the use of laxatives
containing anthraquinones.
In 1997, a retrospective analysis of 2229 patients who
used anthraquinone laxatives was carried out in search of
a relation between melanosis coli and the use of laxative
withthedevelopmentofcolorectalcancer[38].Althoughthe
colorectal adenomas were found with a greater frequency in
patients with melanosis than those without, the presence of
colorectal cancer was not associated with melanosis coli or
the use of laxatives.
The adenomas related with melanosis coli were signiﬁ-
cantly smaller than those not associated with melanosis coli
(P<. 0001) and were located predominantly in the proximal
colon. Diﬀerences in the degree of dysplasia or adenomas
between patients with or without melanosis coli were not
found either [38].
It seems there is no association between colorectal cancer
and melanosis coli or the use of laxatives. Although the
colorectal adenomas are found more frequently in patients
withmelanosiscoli,theydonotcontainthemelaninpigment
type.Theassociationofadenomaswithmelanosiscolicanbe
explained by the easy detection of polyps as white stains in a
dark colored colonic mucosa [39].
As has already been indicated, the chronic use of sen-
noside laxatives on some occasions causes pseudomelanosis
coli [40] and this has been associated to an increase in
the risk of colorectal cancer [41]. In patients subjected to
enemas containing senna extracts, it was observed that the
sennosides induce an acute massive loss of intestinal cells,
possibly because of apoptosis, and alter the length of the
colonic crypts causing the appearance of shorter crypts and
an increase of the cellular proliferation and inhibition of
the restoring apoptosis of the cellular function. These eﬀects
could be the basis of the mechanism that would explain
as u p p o s e dc a n c e rp r o m o t e re ﬀect of the chronic use of
sennosides [40]. It has been proven that the sennosides
administered in an acute manner induce apoptosis of the
epithelial cells of the colon, supposedly through the protein
p53“genomeguardian,”mediatedbyp21/WAF,whichresults
in shorter crypts. In conditions where severe melanosis coli
was observed, apoptosis seems to be delayed, causing longer
crypts without an increase of the proliferating activity or
the expression of bcl-2, antiapoptotic gene. It has been
suggested that the loss of a possible protective mechanismJournal of Toxicology 5
may increase the risk of carcinogenesis during the chronic
use of sennosides [41].
The focus of aberrant crypts is microscopic lesions of the
colon mucosa which is suspected to be preneoplastic. The
research was carried out to evaluate the cause-eﬀect relation
between putative risk factors and colorectal cancer [11, 42,
43]. The anthraquinonic glycosides have been signaled as
weak inducers of aberrant crypt foci in the rat colon mucosa
[11], and, therefore, weak promoters of carcinogenesis of rat
colon. The introduction in the rat diet of high dose of senna
after 56 days did not provide evidence of the appearance
of aberrant crypt foci and only enhanced the activity of
dimethyl hydrazine, known inducer of aberrant crypt foci,
when the highest doses of anthraquinonic glucosides were
evaluated.
In another study carried out in rats treated daily for
13–28 weeks with 10mg/kg PO of senna pods extract, a
weak laxative eﬀect was observed, which did not provoke an
increase of the aberrant crypt foci or tumors in the rat colon;
while a diarrheogenic dose (100mg/kg), capable of inducing
chronic diarrhea for three months, increased the appearance
of induced tumors by azoximethan known tumor inducer
[42]. It is worth mentioning that the usual daily dose in
humans is of 0.4mg/kg.
In a study carried out in the Universita di Napoli,
Italy, and published in 2005, the carcinogenic potential of
the anthraquinones used was evaluated using an extract
of senna pods. With this objective, healthy rats and rats
treated with a tumor-indicating agent of azoximethan were
included. The rats were administered 30 and 60mg/kg
of the senna extract for 110 weeks with no development
of aberrant crypt foci or tumors in the healthy rats.
Surprisingly, the rats that had already been treated with
azoximethanreducedtheaberrantcryptfociandthetumors,
suggesting that a chronic treatment with senna does not
predispose to colon cancer and that in contrast, senna
could have an antitumoral eﬀect on the colon carcinogenesis
[44].
Some years earlier in a review which tried to establish if
the stimulating laxatives were harmful for the colon, it was
assured that there was no reliable data that connected the
chronic use of stimulating laxatives of colorectal cancer and
other tumors. In the same article, it was indicated that the
risks of stimulating laxatives had been overemphasized and
that this had minimized its use by doctors [33].
Another study with patients with sigmoidal cancer and
diverticular disease studied the possible association between
sigmoidalcancerandconstipation,useofanthranoidlaxative
and melanosis coli using the analysis of aberrant crypt foci as
an additional research tool. In the study, 55 surgical patients
with sigmoidal cancer were included, 41 surgery patients
with diverticular disease, and 96 subjects without intestinal
illness. Constipation and use of anthranoid laxatives were
similar between patients with sigmoidal cancer (30.9% and
32.7%, resp.) and those with diverticular disease (39% and
26.8%) but greater than in the controls (18.8% and 8.3%).
Melanosis coli was found in 38.2% of the patients with
sigmoidal cancer and in 39% of those with diverticular
disease. The median frequency of aberrant crypt foci was
greater in patients with cancer sigmoidal (0.24/cm2) than in
those with diverticular disease (0.10/cm2) and did not vary
according to constipation, use of laxatives or melanosis coli
in any of the groups. In this study, the hypothesis of a cause-
eﬀect relationship of the colorectal cancer with constipation,
use of anthranoid laxatives, and melanosis coli was discarded
[43].
6. Colorectal Cancer
In the Melbourne colorectal cancer study that included 685
cases of cancer colorectal and 723 controls, it was found
that chronic constipation self-reported was more common
between the cases of cancer than in the controls. Constipa-
tion was discarded as a risk factor of intestinal cancer once
previously determined dietary risk factors were included,
indicating that the diet was associated with the risk of large
intestine cancer and not constipation. A greater relationship
was established with those that consumed greater amounts
of fat. This study concluded that it is unlikely that chronic
constipation, diarrhea, and the frequency and consistency of
intestinal movement, as well as the use of laxatives, are the
etiological factors in the development of colorectal cancer
[45].
A retrospective study was carried out in 1993 with 2277
patients following a colonoscopy to determine if the use
of laxatives and the existence of melanosis coli diagnosed
by endoscopy were risk factors for colorectal neoplasm.
Results indicated that there was no increase in the rate
of colorectal cancer neither in patients that used laxatives
nor in those with melanosis coli. However, there was very
signiﬁcant association between the appearance of colorectal
adenomas and use of laxatives (between all patients: 1.72;
patients that use laxatives without melanosis coli: 1.47).
The relative risk of developing adenoma in patients with
melanosis coli was 2.19. Since polyps can be diagnosed easily
in the dark mucous of patients with melanosis coli, the
authors of this study concluded that the risk of 2.19 seemed
to be related to a generalized risk of laxative intake rather
than a special group of laxatives that contain anthranoids
[46].
A prospective study carried out in the Erlangen Univer-
sity, Germany, investigated the risk of the use of anthranoid
laxatives in the development of colorectal adenomas or
carcinomas. A total of 202 patients with a recent diagnosis
of carcinoma colorectal, 114 patients with adenomatous
polyps,and238controlpatientswithoutcolorectalneoplasm
were included. The use of anthranoid preparations was
established in a standard interview, and the existence of
melanosis coli visible endoscopically or by microscope
was studied by a histopathological exam. There was no
statistically signiﬁcant risk for the use of anthranoids in
the development of colorectal adenomas or carcinomas. The
presence of macroscopic or microscopic melanosis coli was
not a signiﬁcant risk factor for the development of adenomas
or carcinomas. The authors concluded that neither the use
of long-term anthranoid laxatives nor melanosis coli were
associated with a signiﬁcant risk of developing colorectal
adenoma or carcinoma [47].6 Journal of Toxicology
In experimental studies carried out in 1993, the eﬀects
of the sennosides on cellular proliferation of the epithelium
of the ileum and the large intestine were analyzed in rats in
vivo.CellproliferationwasexaminedbytheBrdUrdlabelling
technique after 2, 6, and 12 weeks of continuous treatment.
None of the laxatives used, bisacodyl, sennosides, sodium
picosulphate, and lactulose, provoked an increase in the
cellular proliferation as determined by the techniques used,
and the pattern of proliferation remained constant along the
crypts. The author concluded the study conﬁrming that the
contactlaxativesdonothaveinﬂuenceontheproliferationof
the colon and should not be considered as tumor-promoting
substances [48].
Subsequently, another article described that danthrone
and sennoside A induced a signiﬁcant cellular proliferation
in the intestine of male F344 rats, after oral administration
for 7 days. This eﬀect was dependent on concentration
and occurred throughout the intestinal epithelium. Signif-
icantly, in the same study, it was indicated that the 1-
hidroxianthraquinone induced a slight proliferation of the
epithelium in the cecum and colorectum with very little or
no toxicity [49].
One of the investigators of the Melbourne Colorectal
cancer study carried out in Australia in 1988 indicated in
1993 that the analysis of the patients that used laxatives
grouped according to the type of laxative used, also allowed
the establishment that the prior use of anthraquinone-like
laxatives was not associated to colorectal cancer risk either
[45]?.
Another study, carried out in rats treated for 2 years with
a puriﬁed sen extract and which was administered through
drinking water, centered on the possible carcinogenicity of
this product, placing special emphasis on gastrointestinal
alterations. The histopathological exam of the gastroin-
testinal tract, liver, adrenal kidneys, and other tissues with
anomalies did not show diﬀerences in the incidence of
neoplasic lesions, concluding that there was no relation
between long-term administration of a senna extract and the
appearance of gastrointestinal tumors or any other type in
rat [32].
Another study on carcinogenicity and toxicity designed a
treatmentof rats with0, 25, 100, and 300mg/kg/day of senna
fruit extracts for 104 weeks. With the results obtained, it was
possible to prove that there was minimal to no hyperplasia
in the colon and cecum. Neoplasic changes associated to the
treatment with senna were not observed in any of the organs.
Based on their results, the authors concluded that senna is
not carcinogenic in rats even after a daily administration for
two years in doses of up to 300mg/kg/day [21].
7. Mutagenicity,Genotoxicity
The mutagenicity of crude senna preparations and of its
glycoside was investigated by Sandnes et al. in 1992 using
diﬀerent strains of Salmonella typhimurium [8]. The fruit
and leaf senna extracts showed a weak activity in some
strains (TA97a, TA100, and TA102). The senna glycosides
were inactive in all strains, except for a slight but signiﬁcant
increase in the mutation frequency of TA102. Nonidentiﬁed
compounds in the crude senna preparations contributed
to the low but biologically signiﬁcant, dose-dependent
mutagenicity (greatest in strain TA98). The weak or absent
activity of the anthraquinone aglycones in the Salmonella
strains assayed indicates that the mutagenicity cannot be
attributed solely to the anthraquinone content of these plant
materials.
Previously, in 1990 using a variety of structurally related
hidroxyanthraquinones, it had been shown that the geno-
toxicity depends on certain structural requirements [12]. In
Salmonella, the majority of compounds assayed were muta-
genicon strain TA1537, butonlythe hydroxyanthraquinones
with a hydroxymethyl side chain such as lucidin and aloe-
emodin were active on other strains. In V79 cells only
those with 2 hydroxy groups in the 1, 3 positions such as
1,3-dihydroxyantraquinone, purpurin, and emodin or those
with a hydroxymethyl side chain (lucidin and aloe-emodin)
were mutagenic.
Other genotoxicity studies have been carried out by
various laboratories with senna fructus, senna extract,
sennosides, rhein, and aloe-emodin. The ﬁrst three did
not increase the mutation frequency in the following
tests: bacterial systems (reverse mutation test in Salmonella
and/or mutation test in Escherichia coli), mammal cell
cultures (hypoxanthine guanine phosphorybosiltransferase
test, lymphoma test in rat, chromosome aberration test with
Chinese hamster ovary cells), medulla osea (micronucleus
test, chromosomal aberration test), and melanoblast cells
of rats (stain test in rat). Aloe-emodin showed mutagenic
eﬀects in vitro in the chromosome aberration test with
Chinese hamster ovarian cells and in the Salmonella test.
In in vivo studies, in the micronuclear test with NMRI
rat germ cells, chromosome aberration test with Wistar rat
germ cells, and others, there were no indices of mutagenic
activity for aloe-emodin. The relevance of the absence
of mutagenic potential in in vivo test systems was re-
enforced by the fact that aloe-emodin could be found in
the sanguine plasma after an oral administration of senna
[10].
Sennaextractshavebeendeﬁnedasnonmutagenicandas
inhibitors of the mutagenicity induced by benzo[a]-pyrene,
shamma, aﬂatoxin B1, and methyl methanosulfonate in
the AMES histidine reversion assay using the Salmonella
typhimurium test strain TA98 [50].
The determination of the genotoxicity proﬁle of senna
products, particularly emodin and aloe-emodin in light of
other metabolism data in animals and humans or kinetic
studies, clinical assays in humans and carcinogenic studies
do not support the aﬃrmation that senna-based laxatives
mean a genotoxic risk in humans when ingested according
to a prescription [51].
Anthraquinones glycosides of Cassia angustifolia and
C. ﬁstula were investigated according to their capacity to
induce a clastogenic eﬀect in germ cells of Swiss albino rats.
T h eo r a le x p o s u r et od i ﬀerent doses of anthraquinone and
the equivalent quantities in senna leaves and pods did not
induce a signiﬁcant number of chromosomal aberrations or
aberrant cells. This reaﬃrms the concept that anthraquinone
sennoside B and rhein are weakly genotoxic [9].Journal of Toxicology 7
In vivo genotoxic assays of senna extracts, analytically
well characterized, have shown that after an oral dose
administration of 2,000mg of senna extract/kg to NMRI,
rats of both sexes, equivalent to 119mg of potential rhein/kg,
5.74mg of potential aloe-emodin/kg, and 0.28mg of poten-
tial emodin/kg, did not provoke an increase in the levels
of micronuclei assay in medulla ossea cells. The clastogenic
activity of the senna extract observed in vitro could not be
conﬁrmed in the micronucleus assay. The authors of this
study concluded that there is no conclusive indication that
there is a risk of genotoxicity for patients who consume
senna-based laxatives [52].
Asasummary,thisanalysisestablishesthat(1)thereisno
convincing evidence that the chronic use of senna brings as a
consequence a structural and/or functional alteration of the
enteric nerves or of the smooth intestinal muscle, (2) there is
no relation between the long-term administration of a senna
extract and the appearance of gastrointestinal tumors or of
any other type in rat, (3) senna is not carcinogenic in rats
even after a daily administration during 2 years in dose up to
300mg/kg/day, and (4) the evidence currently available does
not show that there is a risk of genotoxicity for patients who
consume senna-based laxatives.
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